Company profile: CASI Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of business development aimed at building a pipeline through mutually beneficial transactions.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CASI Pharmaceuticals
Rakuten Medical
HQ: United States
Website
- Description: Provider of investigational cancer therapies based on the proprietary Alluminox photoimmunotherapy platform, which combines a drug with targeting moieties and a light-activating device using non-thermal illumination to selectively target cancer cells; includes ASP-1929, an Alluminox-developed drug with dye-conjugated targeting moieties, approved in Japan for treating certain cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rakuten Medical company profile →
CoRegen
HQ: United States
Website
- Description: Provider of SRC-3 and Treg-focused therapies: SRC-3 KO Treg Therapy that engineers Treg cells to infiltrate and destroy tumors; an SRC-3 small molecule inhibitor that blocks transcriptional activity to inhibit cancer growth and boost immune response; an SRC-3 small molecule enhancer to reduce inflammation and improve tissue repair in myocardial infarction and stroke; and Treg engineering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoRegen company profile →
BioImagene
HQ: United States
Website
- Description: Provider of digital pathology solutions for clinical diagnostics and drug discovery, delivering integrated hardware and software systems to acquire, view, share, manage, archive, and analyze tissue images in pathology laboratories, including IHC algorithms such as HER2, ER/PR, and p53.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioImagene company profile →
Tilos Therapeutics
HQ: United States
Website
- Description: Provider of antibody therapeutics targeting key immunological pathways, with a focus on regulatory T cells and effector cell regulation; developing anti-LAP antibodies specific to the Latency Associated Peptide of TGF beta for cancer treatment. Founded in 2016 and based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilos Therapeutics company profile →
Mirati Therapeutics
HQ: Canada
Website
- Description: Provider of novel cancer therapeutics in clinical development and commercialization; product candidates include MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirati Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CASI Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CASI Pharmaceuticals
2.2 - Growth funds investing in similar companies to CASI Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CASI Pharmaceuticals
4.2 - Public trading comparable groups for CASI Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →